Publicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (84)

2024

  1. De-imFAR phase II project: a study protocol for a cluster randomised implementation trial to evaluate the effectiveness of de-implementation strategies to reduce low-value statin prescribing in the primary prevention of cardiovascular disease

    BMJ Open, Vol. 14, Núm. 4

  2. Elimination of hepatitis C virus in a prison: An 18-year experience

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 5, pp. 236-241

  3. Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta

    Biomedicine and Pharmacotherapy, Vol. 175

  4. Intranasal esketamine and manic symptoms: A disproportionality analysis in EudraVigilance

    European Neuropsychopharmacology

  5. [Translated article] Pharmaceuticals in the environment: A hospital pharmacy perspective

    Farmacia Hospitalaria, Vol. 48, pp. TS13-TS20

2023

  1. Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database

    European Journal of Clinical Pharmacology, Vol. 79, Núm. 5, pp. 679-685

  2. Hypersensitivity reactions associated with iron isomaltoside and ferric carboxymaltose

    European Journal of Internal Medicine

  3. Multilocus Genetic Profile Reflecting Low Dopaminergic Signaling Is Directly Associated with Obesity and Cardiometabolic Disorders Due to Antipsychotic Treatment

    Pharmaceutics, Vol. 15, Núm. 8

  4. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma

    Scientific reports, Vol. 13, Núm. 1, pp. 12159

2022

  1. Attachment anxiety as mediator of the relationship between childhood trauma and personality dysfunction in borderline personality disorder

    Clinical Psychology and Psychotherapy, Vol. 29, Núm. 2, pp. 501-511

  2. Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environment

    Science of the Total Environment, Vol. 820

  3. Hazardous drugs (NIOSH's list-group 1) in healthcare settings: Also a hazard for the environment?

    Science of the Total Environment, Vol. 817

  4. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

  5. Subacute thyroiditis and COVID-19 vaccines: a case/non-case study

    Endocrine, Vol. 77, Núm. 3, pp. 480-485

  6. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study

    Annals of medicine, Vol. 54, Núm. 1, pp. 379-392

2021

  1. A multicenter case–control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users

    Scientific Reports, Vol. 11, Núm. 1

  2. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study

    European Neuropsychopharmacology, Vol. 50, pp. 107-111

  3. Factors influencing the effect of aripiprazole on prolactin levels in patients treated with risperidone or paliperidone. Sex seems to matter

    Schizophrenia Research, Vol. 228, pp. 382-384

  4. Pharmacotherapeutic management of Parkinson's disease inpatients: How about asking hospital pharmacists?

    European Journal of Hospital Pharmacy, Vol. 28, Núm. e1, pp. E140-E145

  5. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10